TUMOR NECROSIS AS A CORRELATE FOR RESPONSE IN SUBGROUP OF PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH SORAFENIB

被引：0
|
作者：
Abou-Alfa, G. K. [1 ]
Zhao, B. [1 ]
Capanu, M. [1 ]
Guo, P. [1 ]
Liu, F. [1 ]
Jacobs, G. [1 ]
Gansukh, B. [1 ]
Moscovici, M. [2 ]
Lentini, G. [3 ]
Schwartz, L. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[2] Bayer SpA PH, Med, Milan, Italy
[3] Bayer Vital GmbH, Gi Oncol, Leverkusen, Germany
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：178 / 178
页数：1
相关论文
共 50 条
  • [31] Targeted genome profiling in patients with advanced hepatocellular carcinoma treated with sorafenib
    Kang, Wonseok
    Kim, Kyung
    Lee, Joon Hyeok
    Lim, Ho Yeong
    Park, Woong-Yang
    Lee, Jeeyun
    Paik, Yong Han
    CANCER RESEARCH, 2017, 77
  • [32] Analysis of postprogression survival of patients with advanced hepatocellular carcinoma treated with sorafenib
    Wada, Y.
    Takami, Y.
    Matsushima, H.
    Ryu, T.
    Mikagi, K.
    Saitsu, H.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S630 - S631
  • [33] Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
    Otsuka, Taiga
    Eguchi, Yuichiro
    Kawazoe, Seiji
    Yanagita, Kimihiko
    Ario, Keisuke
    Kitahara, Kenji
    Kawasoe, Hiroaki
    Kato, Hiroyuki
    Mizuta, Toshihiko
    HEPATOLOGY RESEARCH, 2012, 42 (09) : 879 - 886
  • [34] Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik-Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han Chong
    Gorbunova, Vera
    Eskens, Ferry
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [35] Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
    Chen, D.
    Zhao, P.
    Li, S. -Q.
    Xiao, W. -K.
    Yin, X. -Y.
    Peng, B. -G.
    Liang, L. -J.
    EJSO, 2013, 39 (09): : 974 - 980
  • [36] Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib
    Antonelli, G.
    Gigante, E.
    Iavarone, M.
    Begini, P.
    Sangiovanni, A.
    Iannicelli, E.
    Biondetti, P.
    Pellicelli, A. M.
    Miglioresi, L.
    Marchetti, P.
    Lampertico, P.
    Marignani, M.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (01) : 14 - 14
  • [37] Mutation profiles in circulating tumor DNA (ctDNA) to predict the efficacy of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC).
    Yang, Ping
    Ji, Guanghui
    Jiang, Qionghui
    Lu, Zejun
    Yu, Yao
    Yang, Yadong
    Jin, Ge
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] SKIN TOXICITY AS A PREDICTIVE FACTOR FOR TUMOR CONTROL IN ADVANCED HCC PATIENTS TREATED WITH SORAFENIB
    Vincenzi, B.
    Montella, L.
    Santini, D.
    Venditti, O.
    Addeo, R.
    Frezza, A.
    Del Prete, S.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 52 - 52
  • [39] A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
    Yopp, A.
    Zhu, H.
    Mansour, J.
    Singal, A.
    Arriaga, Y.
    Beg, S.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S34 - S35
  • [40] Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
    Palmer, D. H.
    Hussain, S. A.
    Smith, A. J.
    Hargreaves, S.
    Ma, Y. T.
    Hull, D.
    Johnson, P. J.
    Ross, P. J.
    BRITISH JOURNAL OF CANCER, 2013, 109 (04) : 888 - 890
12345